Skip to content

Contact +44 (0) 20 7060 7474 email us

Diagnostics

HighGrowth Diagnostic Markets

 

Publication Date November 2008
Publisher TriMark Publications
Product Type Report
Pages 310
ISBN Number not applicable
Product Code TRI00090

Price

£2,245.00
approximately: $3,399 | €2,506

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

There will be a steady increase in demand for new diagnostic testing services in the next fiveyear period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this TriMark Publications report is on those companies that are actively developing and marketing highgrowth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the highgrowth diagnostic testing technologies. Moreover, this exanimation provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market highgrowth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category.

Contents

  • 1. Overview
    • 1.1 Statement Of Report
    • 1.2 Scope Of This Report
    • 1.3 Methodology
    • 1.4 Executive Summary
  • 2. Sector Overview
    • 2.1 Global Diagnostic Products Industry
  • 3. HighGrowth Testing Markets: Market Segment Analysis: Size, Growth And Share
    • 3.1 Global HighGrowth Diagnostic Testing Markets
      • 3.1.1 Market Drivers In The HighGrowth Diagnostics Testing Sector
      • 3.1.2 Market Segments For HighGrowth Testing
      • 3.1.3 Key Players In The HighGrowth Diagnostics Testing Segment
      • 3.1.4 HighGrowth Testing Sector Analysis
    • 3.2 U.S. HighGrowth Testing Market
      • 3.2.1 Market Overview
      • 3.2.2 Diagnostic Test Categories
    • 3.3 European HighGrowth Diagnostic Test Market
      • 3.3.1 German Diagnostic Markets
      • 3.3.2 U.K. Testing Diagnostic Market
        • 3.3.2.1 U.K. Market Statistics
        • 3.3.2.2 U.K. Competitive Analysis
        • 3.3.2.3 U.K. Market Access
    • 3.4 Japanese Diagnostic Testing Market
    • 3.5 Chinese Diagnostic Testing Market
  • 4. HighGrowth Testing Individual Markets
    • 4.1 Hepatitis Serologic Markers And Nucleic Acid Testing
      • 4.1.1 Hepatitis B Virus (Hbv)
      • 4.1.2 Hepatitis C Virus (Hcv) Testing
      • 4.1.3 Hepatitis B Virus/Hepatitis C Virus Viral Load And Drug Resistance
  • 5. Cardiac Markers
    • 5.1 Market Overview
      • 5.1.1 American Market
      • 5.1.2 European Market
    • 5.2 Acute Myocardial Infarction
    • 5.3 Heart Failure (Bnp)
      • 5.3.1 Market Overview
      • 5.3.2 Commercial Assays For Bnp And NtProbnp
      • 5.3.3 Market Share
    • 5.4 Crp
    • 5.5 Pulmonary Embolism (DDimer Test)
    • 5.6 Key Players
  • 6. Cytogenetic Testing
    • 6.1 Cancer Testing
    • 6.2 Prenatal Testing And Cytogenetics
      • 6.2.1 Cystic Fibrosis Testing
        • 6.2.1.1 Cf Testing Methodology
        • 6.2.1.2 Cf Screening Technology Summary
    • 6.3 Key Players In Segment
  • 7. Fertility Testing
  • 8. Clinical Laboratory Genomics
    • 8.1 Introduction
    • 8.2 Clinical Laboratory Genomics Testing
    • 8.3 Developments In Clinical Laboratory Genomics
      • 8.3.1 Nucleic Acid Amplification Techniques
      • 8.3.2 Chromosome Imaging
      • 8.3.3 Genomics Technologies
      • 8.3.4 Proteomics Technology
      • 8.3.5 Current Pharmacogenomic Tests
      • 8.3.6 Future Pharmacogenomic Testing
  • 9. Glucose Monitoring
    • 9.1 Overview Of Market Segment
    • 9.2 Competitive Strategies
    • 9.3 Analyses Of The Current Market Conditions, Competition And Product Mix
      • 9.3.1 FirstGeneration Monitors
      • 9.3.2 SecondGeneration Monitors
      • 9.3.3 ThirdGeneration Smbg Technologies
      • 9.3.4 Other Monitoring Device Advancements
  • 10. Cancer Biomarker Testing
    • 10.1 Segment Overview
    • 10.2 The Cancer Testing Market
    • 10.3 Competition
    • 10.4 Individual Markets
      • 10.4.1 Cancer Pathology: Testing
        • 10.4.1.1 Rare Cell/Micro Metastasis Detection
        • 10.4.1.2 Cancer Pathology: HighThroughput Screening
        • 10.4.1.3 Competition
        • 10.4.1.4 Drivers
      • 10.4.2 Breast Cancer
        • 10.4.2.1 Ca
        • 10.4.2.2 Ca
        • 10.4.2.3 Brca1 And Brca2 Breast And Ovarian Cancer Genes
        • 10.4.2.4 Estrogen And Progesterone Receptor (Er And Pr)
        • 10.4.2.5 Her2
        • 10.4.2.6 Herceptin
        • 10.4.2.7 P53
        • 10.4.2.8 Nmp66
        • 10.4.2.9 Mammastatin
        • 10.4.2.10 Drivers For Breast Cancer Test Development
      • 10.4.3 Ovarian Cancer
        • 10.4.3.1 Ca 125 Ii
        • 10.4.3.2 Brca1 And Brca2
        • 10.4.3.3 Steroid Hormone Receptors
        • 10.4.3.4 Epidermal Growth Factor Receptor (Egfr)
        • 10.4.3.5 Lysophospholipids
      • 10.4.4 Cervical Cancer
      • 10.4.5 Colon Cancer Dna Testing
    • 10.5 Pharmacogenomic Cancer Testing
  • 11. Hpv Testing
    • 11.1 Overview
    • 11.2 U.S. Market
    • 11.3 European Market
    • 11.4 Other Markets
    • 11.5 The Association Of Hpv And Cervical Cancer
    • 11.6 Assays For Hpv
  • 12. Biochips For Clinical Applications
    • 12.1 Roche Amplichip
    • 12.2 Amersham Codelink
    • 12.3 Breast Cancer Dna Chips
    • 12.4 Osmetech Esensor
    • 12.5 Affymetrix Genechip System 3000dx V.2
    • 12.6 Caliper And Cepheid
    • 12.7 Agilent Technologies 2100 LabOnAChip
  • 13. Hiv
    • 13.1 U.S. Testing Market
    • 13.2 World Testing Market
      • 13.2.1 Asia
      • 13.2.2 Japan
      • 13.2.3 SubSaharan Africa
      • 13.2.4 Rest Of World
    • 13.3 Major Players
  • 14. Cellular Imaging Cytopathology And Histopathology
    • 14.1 Segment Overview
    • 14.2 The Market
    • 14.3 Market Drivers
    • 14.4 Market Restraints
    • 14.5 Cytology And Histology Technology Platforms
      • 14.5.1 Cytology Screening Procedures And Pap Smear Technology
      • 14.5.2 Histology
      • 14.5.3 Market Drivers
      • 14.5.4 Ish Staining
      • 14.5.5 SpecialStains Staining
    • 14.6 ThirdParty Reimbursement
    • 14.7 Competition
  • 15. Infectious Disease Testing
    • 15.1 Streptococcus Testing
    • 15.2 Chlamydia Testing
    • 15.3 Mononucleosis
    • 15.4 Gonorrhea
    • 15.5 Influenza
    • 15.6 Malaria
    • 15.7 Tuberculosis
    • 15.8 MethicillinResistant Staphylococcus Aureus (Mrsa)
  • 16. HighGrowth Testing Diagnostic Trends
    • 16.1 Genetic Testing
    • 16.2 Quality Measures
    • 16.3 Moderators Of Growth
      • 16.3.1 Diagnostics And The Aging Population
      • 16.3.2 Individualized Medicine
      • 16.3.3 Genetic Testing
    • 16.4 Workforce Issues
    • 16.5 Reimbursement
      • 16.5.1 Cardiovascular
      • 16.5.2 Screening For Diabetes
      • 16.5.3 Cpt Test Codes And Payment Amounts
    • 16.6 Rapid NearPatient Testing In Hospitals
    • 16.7 Satellite Facilities
    • 16.8 Regionalization Of Laboratory Care
    • 16.9 Requirements For HighGrowth Testing
    • 16.10 Clinical Laboratory Improvement Act (Clia)
  • 17. Business Trends In The Industry
    • 17.1 Sector Consolidation
    • 17.2 Diagnostic Testing Growth Trends
    • 17.3 Acquisition, License Agreements, Internal Development, Partnerships
    • 17.4 Product Testing Depth In HighGrowth Testing
    • 17.5 Government Regulation
      • 17.5.1 U.S. Regulations
        • 17.5.1.1 Importing Medical Devices Into The U.S
        • 17.5.1.2 Exporting Medical Devices From The U.S
      • 17.5.2 U.K Regulations
      • 17.5.3 E.U. Regulations
      • 17.5.4 Japanese Regulations
    • 17.6 Increased Market Penetration In HighGrowth Testing
  • 18. Important Technology Trends
  • 19. Company Profiles
    • 19.1 Accurex Biomedical, Pvt., Ltd
    • 19.2 Adeza Biomedical Corporation (Hologic)
    • 19.3 Agilent Technologies, Inc
    • 19.4 Ambri, Ltd
    • 19.5 American Bio Medica Corp
    • 19.6 Ani Biotech
    • 19.7 Applied Spectral Imaging
    • 19.8 Avitar, Inc
    • 19.9 AxisShield
    • 19.10 Bayer Corporation
    • 19.11 Beckman Coulter
    • 19.12 Becton Dickinson
    • 19.13 Biomerica
    • 19.14 BioRad, Inc
    • 19.15 Cozart Bioscience
    • 19.16 Denka Seiken Co., Ltd
    • 19.17 Diadexus Llc
    • 19.18 Enterix, Inc. (Subsidiary Of Quest Diagnostics)
    • 19.19 Genetix
    • 19.20 Genzyme Diagnostics
    • 19.21 Hologic, Inc
    • 19.22 Iatron
    • 19.23 Inverness Medical Innovations
    • 19.24 Jiangnan Biotech
    • 19.25 Johnson & Johnson
    • 19.26 Kyowa Medex Co., Ltd
    • 19.27 Lifepoint, Inc
    • 19.28 Lifescan
    • 19.29 Matritech
    • 19.30 Medix Biochemica
    • 19.31 Myriad Genetics
    • 19.32 Orasure
    • 19.33 Pheromone Sciences
    • 19.34 Polymedco
    • 19.35 Procrea
    • 19.36 Qiagen
    • 19.37 Quidel
    • 19.38 Roche Diagnostics
    • 19.39 Shanghai Siic Kehua Biotech Co., Ltd. (Kehua Biotech)
    • 19.40 Shionogi & Co
    • 19.41 Siemens
    • 19.42 Spectral Diagnostics, Inc
    • 19.43 Third Wave Technologies
  • 20. Appendix 1: Opportunities In The Chinese Biotech Market
  • 21. Appendix 2: Opportunities In The Indian Diagnostics Market
    • Index Of Tables
    • Table 1.1: Emerging Technology Platforms Driving HighGrowth Diagnostics Market Segments
    • Table 1.2: Market Trends In The HighGrowth Diagnostics Space
    • Table 2.1: U.S. Population Dynamics, 20052015
    • Table 2.2: World Population And Growth, 20002025
    • Table 2.3: Total Japanese Population And Aging Demographics Forecast
    • Table 2.4: Worldwide Market Share In Vitro Diagnostic Companies, 2007
    • Table 2.5: Worldwide In Vitro Diagnostics Market Size, 20032012
    • Table 2.6: U.S. In Vitro Central Lab Diagnostic Testing, 20032012
    • Table 2.7: Worldwide NearPatient Diagnostic Testing, 20022012
    • Table 3.1: HighGrowth Market Segments Overview, 2008
    • Table 3.2: U.S. HighGrowth Diagnostic Testing Market Segments, 2007
    • Table 3.3: Regional Comparison Of Gdp, Healthcare And Ivd, 2006
    • Table 3.4: German Diagnostics Products Market Sales, 20002008
    • Table 3.5: The German Patient Care Lab Test Market, 20022012
    • Table 3.6: The German Alternate Site Testing Market (Pol), 20022012
    • Table 3.7: The German Hospital Point Of Care Market, 20022012
    • Table 3.8: German Clinical Diagnostic Rapid Test Market Segments
    • Table 3.9: List Of Diagnostics Companies In The U.K
    • Table 3.10: Major U.K. Ivd Manufacturers
    • Table 3.11: U.S. Ivd Manufacturers Doing Business In The U.K
    • Table 3.12: Other European Companies That Manufacture Ivd Products In The U.K
    • Table 3.13: Japanese In Vitro Diagnostic Testing Market, 20002012
    • Table 3.14: Japans Diagnostics Market Sales, 19972006
    • Table 3.15: Companies With Leading Market Share Of Japanese Diagnostics, By Segment
    • Table 3.16: Chinese Diagnostics Products Market Sales, 20002012
    • Table 3.17: Disease Burden In China: Urban And Rural
    • Table 4.1: Global Market For Hbv Diagnostic Testing, 20002012
    • Table 4.2: U.S. Market For Hbv Diagnostic Testing, 20002012
    • Table 4.3: Serological Diagnosis Of Hepatitis B Virus Infections
    • Table 4.4: Lower Detection Limits Of Hbv Dna Assays
    • Table 4.5: Summary Of Hepatitis B Test Technology
    • Table 4.6: Global Market For Hcv Diagnostic Testing, 20002008
    • Table 4.7: U.S. Market For Hcv Diagnostic Testing, 20002008
    • Table 4.8: Efficiency Of Available Hcv Screening Tests
    • Table 4.9: Recommendations For Diagnostic Testing For Hepatitis C
    • Table 4.10: Hepatitis C Statistics
    • Table 4.11: GenProbe Clinical Diagnostic Products Test For The Detection Of Hcv
    • Table 5.1: Biomarkers In Heart Failure
    • Table 5.2: Medication Chart For Cardiovascular Disease
    • Table 5.3: Acute Myocardial Infarction Facts
    • Table 5.4: Emergency Room Admissions In The U.S., 19972005
    • Table 5.5: Market Growth Drivers For Cardiac Markers
    • Table 5.6: Market Barriers To Growth For Cardiac Markers
    • Table 5.7: Specific Cardiac Markers
    • Table 5.8: Cardiac Markers After Onset Of Myocardial Infarction
    • Table 5.9: The Cardiac Marker Market For Testing In The U.S., 20012010
    • Table 5.10: Market Share Of Cardiac Marker Segment
    • Table 5.11: U.S. Market For Point Of Care Cardiac Marker Testing, 20002010
    • Table 5.12: Bnp Characteristics
    • Table 5.13: Global Sales Of Bnp Diagnostic Tests, 20002010
    • Table 5.14: Market Share Of Bnp Assays In The U.S
    • Table 5.15: Market Share Of NtProbnp Assays In The U.S
    • Table 5.16: Cardiovascular Risk Classification By Crp Level
    • Table 5.17: Clinical Characteristics Of DDimer
    • Table 6.1: Global Market For Cancer Cytogenetic Diagnostic Testing, 20002012
    • Table 6.2: U.S. Market For Cancer Cytogenetic Diagnostic Testing, 20002012
    • Table 6.3: Genetic Testing: Consequences And Challenges
    • Table 6.4: Cf Carrier Risk By Ethnic Group
    • Table 6.5: Reasons For Cf Testing
    • Table 6.6: Cf Gene Detection Rates Vary By Ethnic Background
    • Table 6.7: Global Market For Cf Diagnostic Testing, 20002010
    • Table 6.8: U.S. Market For Cf Diagnostic Testing, 20002010
    • Table 6.9: Commercial Cf Screening Products
    • Table 6.10: Emerging Cf Screening Products
    • Table 7.1: The Fertility Testing Market In The U.S., 20002008
    • Table 9.1: U.S. Population Of Diabetics By Group
    • Table 9.2: Percentage Of U.S. Adults Using Diabetes Medication, By Age,
  • 19972006
    • Table 9.3: Health Care Utilization By The Diabetes Patient
    • Table 9.4: The Global Population Of Persons With Diabetes, 1995 And 2025
    • Table 9.5: Market For Glucose Testing In The U.S., 20012012
    • Table 9.6: The Worldwide Market For Glucose Testing, 20002012
    • Table 9.7: Major Players In Point Of Care And NearPatient Testing For Otc Glucose Meters
    • Table 10.1: Womens Cancer Incidence Estimates In The U.S., 2008
    • Table 10.2: FiveYear DiseaseFree Survival By Stage At Diagnosis
    • Table 10.3: Tpa Marker Sensitivity
    • Table 11.1: Hpv Risk Factors
    • Table 11.2: Hpv And Cervical Carcinoma
    • Table 11.3: Global HpvTesting Market Size, 20032011
    • Table 11.4: Hpv And Cervical Carcinoma Risk
    • Table 11.5: Reflex Hpv Testing With Cytology
    • Table 11.6: Predictability Of Hpv Test By Abnormal Pap Smear Type
    • Table 11.7: Incidence Of Cervical Cancer And Cytological Abnormalities
    • Table 11.8: LongTerm Trends In Hpv Testing
    • Table 12.1: Biochip Revenues And Growth Rates By Application
    • Table 12.2: Total Biochip Market: Worldwide Revenue Forecasts, 20002010
    • Table 12.3: Total Biochip Market: U.S. Revenue Forecasts, 20002010
    • Table 13.1: Aids Statistics For The U.S.: Diagnoses, Deaths And Burden, 20022006
    • Table 13.2: U.S. Hiv Statistics, 2007
    • Table 13.3: Births Of Hiv Infected Babies In U.S., 20002009
    • Table 13.4: Rapid Hiv Tests On The Market
    • Table 13.5: U.S. HighGrowth Testing Market For Hiv, 20012012
    • Table 13.6: Global Hiv Statistics, 2007
    • Table 14.1: Estimated Cervical Cancer Cases/Deaths Worldwide
    • Table 14.2: Medicare Reimbursement For Cervical Pathology Procedures
    • Table 15.1: U.S. Strep Testing Market Size, 20002008
    • Table 15.2: Rapid Strep Tests On The Market
    • Table 15.3: U.S. Market For Rapid Point Of Care Strep Tests
    • Table 15.4: The U.S. Chlamydia Testing Market, 20012009
    • Table 15.5: Rapid Tests For Chlamydia
    • Table 15.6: Rapid Tests For Gonorrhea
    • Table 15.7: CommerciallyAvailable Rapid Tests For Malaria
    • Table 15.8: Find Partners
    • Table 15.9: Global Market Potential For Tb Diagnostic Testing, 20002010
    • Table 15.10: Mrsa Diagnostics Currently On The Market
    • Table 16.1: New Cpt Test Codes Introduced In 2008
    • Table 18.1: Employment Of Clinical Laboratory Workers, 20062016
    • Table 20.1: China Biotech Reagents Market
    • Table 20.2: Biotechnology Projects Between China And The West
    • Table 21.1: Overview Of Healthcare In India
    • Index Of Figures
    • Figure 2.1: U.S. Lab Industry Market Share, 2007
    • Figure 2.2: Major Lab Testing Segments, U.S
    • Figure 3.1: Total Spending On Healthcare In The U.S., 2007
    • Figure 3.2: International Per Capita Spending On Healthcare, 2006
    • Figure 3.3: Japan Ivd Sales By Segment, 2006
    • Figure 14.1: Worldwide Incidence Rates Of Cervical Cancer Per 100,000 Females
    • Figure 15.1: Global Incidence Of Malaria
    • Figure 15.2: Mode Of Action Of Common Malaria Rdt Format
    • Figure 15.3: Find Pipeline For Tb Diagnostics
    • Figure 21.1: Indian Diagnostics Market Segments, 2007